Researchers Identified Proteins Linked to CAPS Inflammation

A study uncovered how gasdermin D and E proteins cause neutrophil rupture in this rare inflammatory condition.

Updated on Oct. 14, 2026 in Diseases — General

Researchers Identified Proteins Linked to CAPS Inflammation

Live Poll

Is it time for medical research to focus on targeting cell-rupture proteins instead of signaling blockers?

Researchers identified gasdermin D and gasdermin E as the proteins responsible for neutrophil rupture in patients with cryopyrin-associated periodic syndrome (CAPS). The findings suggest these pore-forming proteins serve as potential targets for future therapeutic interventions.

Why it matters

Understanding the specific mechanism behind neutrophil bursting helps explain how inflammation and IL-1beta levels rise in patients with this rare condition. This discovery offers a new pathway for developing drugs to mitigate severe inflammatory symptoms.

Researchers utilized mass cytometry to compare inflammatory activity in neutrophils from six patients with CAPS and six healthy donors. The condition affects an estimated one to five in a million people across the United States.

The players

University of California, San Diego

This public research university served as the center for the leadership of this scientific study.

The details

The study revealed that gain-of-function mutations in the NLRP3 gene trigger these proteins to cluster at the cell membrane, causing stiffening and tearing. Experiments in mouse models demonstrated that removing both gasdermin D and E reduces inflammation and improves survival rates.

October 13, 2026: The study was published in Science Signaling.

Health Landscape

This discovery extends the existing understanding of the NLRP3 gene mutation pathway by identifying the specific effectors that cause cell damage. It represents a shift from observing systemic inflammation to identifying the precise pore-forming proteins that drive neutrophil destruction.

While the study provides a new target for drug development, patients should note that therapies specifically addressing these gasdermin proteins have not yet reached clinical testing. Continued research will determine if these findings eventually lead to new treatment options for those living with CAPS.

The takeaway

The research highlights that targeting two distinct proteins, rather than just one, may be necessary to fully resolve the cell ruptures associated with this syndrome. Further clinical trials are essential to determine if this dual-protein approach is safe for human application.